Gelonghui, October 31st 丨 Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that its holding subsidiary, Nanjing Kangchuanji Medical Technology Co., Ltd. (referred to as 'Kang Chuanji Medical'), has received the 'Drug Registration Certificate' for Dopamine Hydrochloride Injection issued by the National Medical Products Administration (Acceptance Number: CYHS2301483). Dopamine Hydrochloride Injection is suitable for shock syndrome caused by myocardial infarction, trauma, endotoxin septicemia, heart surgery, renal failure, and congestive heart failure; especially for shock with oliguria and normal or low peripheral vascular resistance that cannot be corrected after volume supplementation. It was developed by Hospira Pharmaceuticals and was first launched in the USA in 1974.